153 related articles for article (PubMed ID: 31228268)
21. Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y; Zarrella DT; Pooladanda V; Azimi Mohammadabadi M; Kim E; Kumar S; Xu M; Qin X; Ray LJ; Devins KM; Kumar R; Kononenko A; Eisenhauer E; Veillard IE; Yamagami W; Hill SJ; Sarosiek KA; Yeku OO; Spriggs DR; Rueda BR
Br J Cancer; 2024 May; 130(9):1463-1476. PubMed ID: 38438589
[TBL] [Abstract][Full Text] [Related]
22. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
23. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
24. High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
Shen X; Wang J; Deng B; Chen S; John C; Zhao Z; Sinha N; Haag J; Sun W; Kong W; Spasojevic I; Batinic-Haberle I; Secord AA; Zhou C; Bae-Jump VL
Gynecol Oncol; 2024 Apr; 183():93-102. PubMed ID: 38555710
[TBL] [Abstract][Full Text] [Related]
25. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway.
Kovarik P; Stoiber D; Eyers PA; Menghini R; Neininger A; Gaestel M; Cohen P; Decker T
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13956-61. PubMed ID: 10570180
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
27. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
28. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
[TBL] [Abstract][Full Text] [Related]
29. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
Al-Hussaini M; Stockman A; Foster H; McCluggage WG
Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
[TBL] [Abstract][Full Text] [Related]
30. Ryanodine receptor 1-mediated Ca
Zhang L; Au-Yeung CL; Huang C; Yeung TL; Ferri-Borgogno S; Lawson BC; Kwan SY; Yin Z; Wong ST; Thomas V; Lu KH; Yip KP; Sham JSK; Mok SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):242. PubMed ID: 35953818
[TBL] [Abstract][Full Text] [Related]
31. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
Lee EK; Fader AN; Santin AD; Liu JF
Gynecol Oncol; 2021 Jan; 160(1):322-332. PubMed ID: 33160694
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
33. p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy.
Attias-Geva Z; Bentov I; Kidron D; Amichay K; Sarfstein R; Fishman A; Bruchim I; Werner H
Eur J Cancer; 2012 Jul; 48(10):1570-80. PubMed ID: 22033326
[TBL] [Abstract][Full Text] [Related]
34. Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
Tortorella L; Langstraat CL; Weaver AL; McGree ME; Bakkum-Gamez JN; Dowdy SC; Cliby WA; Keeney GL; Sherman ME; Weroha SJ; Mariani A; Podratz KC
Gynecol Oncol; 2018 May; 149(2):291-296. PubMed ID: 29550183
[TBL] [Abstract][Full Text] [Related]
35. MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1.
Vanhatupa S; Ungureanu D; Paakkunainen M; Silvennoinen O
Biochem J; 2008 Jan; 409(1):179-85. PubMed ID: 17897103
[TBL] [Abstract][Full Text] [Related]
36. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
[TBL] [Abstract][Full Text] [Related]
38. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
39. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
40. Tannic acid inhibits EGFR/STAT1/3 and enhances p38/STAT1 signalling axis in breast cancer cells.
Darvin P; Joung YH; Kang DY; Sp N; Byun HJ; Hwang TS; Sasidharakurup H; Lee CH; Cho KH; Park KD; Lee HK; Yang YM
J Cell Mol Med; 2017 Apr; 21(4):720-734. PubMed ID: 27862996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
